Classes
Publications
- The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN (TM)) Mice and Pure Enzymes2015 | Faculty of Science
- The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice2013 | Faculty of Science
- Cytochrome b(5) Increases Cytochrome P450 3A4-Mediated Activation of Anticancer Drug Ellipticine to 13-Hydroxyellipticine Whose Covalent Binding to DNA Is Elevated by Sulfotransferases and N,O-Acetyltransferases2012 | Faculty of Science, Second Faculty of Medicine
- Role of Cytochromes P450 1A1/2 in Detoxication and Activation of Carcinogenic Aristolochic Acid I: Studies with the Hepatic NADPH:Cytochrome P450 Reductase Null (HRN) Mouse Model2011 | Faculty of Science, First Faculty of Medicine, Faculty of Physical Education and Sport
- Cytochrome b(5) shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy2011 | Faculty of Science
- Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney2010 | Faculty of Science
- Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA2008 | Faculty of Science
- Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A22008 | Faculty of Science
- Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH: Cytochrome P450 reductase null mouse +12008 | Faculty of Science
- The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism2007 | Faculty of Science
Loading network view...